US FDA approves Lilly and Incyte’s Olumiant for treating certain hospitalised patients with…
Olumiant is the first and only FDA-approved JAK inhibitor for the treatment of COVID-19 in certain hospitalised adults requiring…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Incyte
Arthritis drug shown to reduce risk of COVID death in large UK trial
More than 8,000 patients were administered baricitinib in addition to usual care, at random, or usual care alone, as part of the…
Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with…
Ruxolitinib (Jakafi) does not prevent complications due to COVID-19 associated cytokine storm: Study
There was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including…